Related Experiment Video

Updated: May 29, 2025

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

10.4K

Erratum: Fulvestrant Versus Anastrozole in Endocrine Therapy-Naïve Women With Hormone Receptor-Positive Advanced

John F R Robertson, Zhimin Shao, Shinzaburo Noguchi

    Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
    |February 7, 2025
    PubMed
    Abstract

    No abstract available in PubMed .

    More Related Videos

    Focal Laser Ablation of Prostate Cancer: An Office Procedure
    11:07

    Focal Laser Ablation of Prostate Cancer: An Office Procedure

    Published on: March 30, 2021

    7.7K
    A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
    07:25

    A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

    Published on: March 6, 2018

    13.0K

    Related Experiment Videos

    Last Updated: May 29, 2025

    Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
    04:04

    Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

    Published on: February 12, 2017

    10.4K
    Focal Laser Ablation of Prostate Cancer: An Office Procedure
    11:07

    Focal Laser Ablation of Prostate Cancer: An Office Procedure

    Published on: March 30, 2021

    7.7K
    A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
    07:25

    A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

    Published on: March 6, 2018

    13.0K

    Related Concept Videos

    Targeted Cancer Therapies02:57

    Targeted Cancer Therapies

    7.4K
    The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
    There are several types of targeted therapies against...
    7.4K

    Articles linked to this work by shared authors, journal, and citation graph.

    Adjuvant alectinib versus chemotherapy in resected ALK-positive non-small-cell lung cancer (ALINA): health-related quality-of-life and safety outcomes from a randomised, open-label, phase 3 trial.

    The Lancet. Oncology·2026

    Continued Cemiplimab Beyond Progression With Addition of Chemotherapy in Patients With Advanced NSCLC With PD-L1 Expression of 50% or Higher: 5-Year Follow-Up From EMPOWER-Lung 1.

    JTO clinical and research reports·2026

    SKYSCRAPER-01: Tiragolumab in Combination With Atezolizumab in Previously Untreated PD-L1-High, Locally Advanced, Unresectable or Metastatic Non-Small Cell Lung Cancer.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

    Disease characteristics and treatment outcomes in patients with resected early-stage ALK-positive non-small cell lung cancer from the randomized ALINA trial.

    Lung cancer (Amsterdam, Netherlands)·2026

    First-Line Cemiplimab for Locally Advanced NSCLC: Updated Subgroup Analyses From the EMPOWER-Lung 1 and EMPOWER-Lung 3 Trials.

    JTO clinical and research reports·2026

    Review of patient-reported outcomes in EMPOWER-Lung 1 in patients with advanced non-small cell lung cancer treated with cemiplimab versus chemotherapy.

    Cancer·2026

    Dalmelitinib Plus Aumolertinib in Advanced NSCLC Patients With EGFR-TKI Resistance and MET Amplification: A Randomized Phase 3 Trial.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

    ENZARAD (ANZUP 1303): Phase 3 Trial of Enzalutamide With Androgen Deprivation Therapy and Radiation Therapy in High-Risk Localized or Locally Advanced Prostate Cancer.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

    Phase II Study of Neoadjuvant Cemiplimab for Stage II to IV Cutaneous Squamous Cell Carcinoma: Final Analysis.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

    COMPANION-002: A Randomized Phase 2/3 Trial of Tovecimig Plus Paclitaxel versus Paclitaxel Alone as a Second-line Therapy in Patients with Advanced Biliary Tract Cancer.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

    Association of Circulating Eosinophils With Systemic Immune Activation and Reduced Recurrence in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

    Hypofractionated Versus Conventionally Fractionated Postmastectomy Radiotherapy With Internal Mammary Node Irradiation for High-Risk Breast Cancer (HypoMast-IMNI): A Randomized Phase III Trial.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

    Time to Treatment Failure as a Recorded Treatment-Process Measure in C-CAT. Reply to Comment on "Facility-Level Medical Oncology Specialist Availability and First-Line Time to Treatment Failure in Lung Cancer: A Nationwide C-CAT Registry Analysis. Curr. Oncol. 2026, 33, 462".

    Current oncology (Toronto, Ont.)·2026

    Does Time to Treatment Failure Measure the Same Clinical Process Across Oncology Facilities? Comment on Kajiura et al. Facility-Level Medical Oncology Specialist Availability and First-Line Time to Treatment Failure in Lung Cancer: A Nationwide C-CAT Registry Analysis. Curr. Oncol. 2026, 33, 462.

    Current oncology (Toronto, Ont.)·2026

    Electroacupuncture Combined with Cognitive Behavioral Therapy for Insomnia Alleviates Insomnia-Anxiety Comorbidity in Gynecological Cancer Patients Undergoing Chemotherapy: A Randomized Controlled Trial.

    Current oncology (Toronto, Ont.)·2026

    [177Lu]Lu-PSMA-617 in Metastatic Hormone-Sensitive Prostate Cancer: Evidence from PSMAddition and Considerations for Treatment Sequencing.

    Current oncology (Toronto, Ont.)·2026

    A New Era of Treatment Sequencing in Platinum-Resistant Ovarian Cancer: Integrating Immunotherapy, Antibody-Drug Conjugates, and Targeted Therapies.

    Current oncology (Toronto, Ont.)·2026

    A Remotely Delivered Exercise-Based Rehabilitation Program for Patients with Persistent Chemotherapy-Induced Peripheral Neuropathy (EX-CIPN): A Phase I Feasibility Trial.

    Current oncology (Toronto, Ont.)·2026
    See all related articles
    JoVE
    x logofacebook logolinkedin logoyoutube logo
    ABOUT JoVE
    OverviewLeadershipBlogJoVE Help Center
    AUTHORS
    Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
    LIBRARIANS
    TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
    RESEARCH
    JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
    EDUCATION
    JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
    Terms & Conditions of Use
    Privacy Policy
    Policies
    Jove
    Visualize
    Contact Us